Interpreting Data on Transplant Selection and Outcome in Adult Acute Lymphoblastic Leukemia (ALL)  Jacob M. Rowe  Biology of Blood and Marrow Transplantation  Volume 17, Issue 1, Pages S76-S83 (January 2011) DOI: 10.1016/j.bbmt.2010.11.024 Copyright © 2011 Terms and Conditions

Figure 1 NRM for patients who underwent an allogeneic transplant. Data not by intention-to-treat analysis. Reproduced with permission from Goldstone et al. [6]. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 2 Meta-analysis of high-risk ALL in 7 studies showing an overall benefit for the donor group. Reproduced with permission from Yanada et al. [11]. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 3 Donor versus no-donor analysis for high-risk patients in the LALA 94 study.Reproduced with permission from Thomas et al. [12]. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 4 Comparison of OS for autologous transplant versus chemotherapy in the MRC UKALLXII/ECOG 2993 study. (A) Data by intention-to-treat analysis, showing the superiority of chemotherapy. Reproduced with permission from Goldstone et al. [6]. (B) Data from the same study by treatment actually received. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 5 Survival from first relapse in 609 patients in the MRC UKALLXII/ECOG 2993 study. (A) Reproduced with permission from Fielding et al. [26]. (B) Survival from allogeneic sibling transplant in CR2. Reproduced with permission from Doney et al. [24]. (C) CIBMTR data over the past decade for ALL. Patients who were transplanted at CR2 or in subsequent remission. Reproduced with permission from Pasquini et al. [25]. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 6 OS for Ph-negative patients treated on the MRC UKALLXII/ECOG 2993 study. (A) Data for high-risk patients as published in 2008 upon completion of study. Reproduced with permission from Goldstone et al. [6]. (B) Data for high-risk patients from the same study presented 5 years earlier, with a shorter follow-up and smaller numbers. (C) Data for standard-risk patients as published in 2008 upon completion of study. Reproduced with permission from Goldstone et al. [6]. (D) Data for standard-risk patients from the same study represented 5 years earlier, with a shorter follow-up and smaller numbers. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions

Figure 7 Ph-positive patients treated on the MRC UKALLXII/ECOG 2993 study, comparing imatinib and preimatinib era. Oral presentation at the 2007 annual meeting of the American Society of Hematology [31]. Biology of Blood and Marrow Transplantation 2011 17, S76-S83DOI: (10.1016/j.bbmt.2010.11.024) Copyright © 2011 Terms and Conditions